NCT04094207View on ClinicalTrials.gov

Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2022

Conditions
Schizophrenia
Interventions
DRUG

Placebo oral tablet

Placebo tablets PLUS Risperidone 2 mg tablet up to 6 mg/day

DRUG

Pentoxifylline

Pentoxifylline tablet PLUS Risperidone 2 mg tablet up to 6 mg/day

Trial Locations (1)

Unknown

Faculty of Medicine, Shibīn al Kawm

All Listed Sponsors
lead

Sadat City University

OTHER

NCT04094207 - Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia | Biotech Hunter | Biotech Hunter